Tvardi Therapeutics, Inc.
TVRDAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jul 8, 2026 | Piper Sandler | $13.00(+160%) | $5.00 | TheFly | |
| Jul 8, 2026 | UBS | Ryan Deschner | $10.00(+223%) | $3.10 | TheFly |
| Jun 8, 2026 | H.C. Wainwright | $9.00(+211%) | $2.89 | TheFly | |
| Apr 20, 2026 | Barclays | $3.00(-12%) | $3.39 | TheFly | |
| Oct 13, 2025 | Barclays | $5.00(-25%) | $6.69 | TheFly | |
| Oct 13, 2025 | Piper Sandler | Yasmeen Rahimi | $4.00(-39%) | $6.54 | TheFly |
| Oct 13, 2025 | Barclays | Etzer Darout | $61.00(+47%) | $41.60 | TheFly |
| Jun 12, 2025 | Piper Sandler | Yasmeen Rahimi | $78.00(+199%) | $26.11 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| BTIG | maintain | Buy | Jul 30, 2026 |
| Raymond James | upgrade | Market Perform →Outperform | Jul 8, 2026 |
| BTIG | maintain | Buy | Jul 7, 2026 |
| Barclays | downgrade | Equal Weight →Underweight | Apr 20, 2026 |
| Barclays | maintain | Equal Weight | Apr 1, 2026 |
| Piper Sandler | maintain | Neutral | Apr 1, 2026 |
| BTIG | maintain | Buy | Apr 1, 2026 |
| Raymond James | downgrade | Outperform →Market Perform | Oct 14, 2025 |
| BTIG | maintain | Buy | Oct 13, 2025 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.57| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.69 | $-0.70 | — | — |
| May 8, 2026 | $-0.73 | $-0.65 | — | — |
| Mar 31, 2026 | $-0.78 | $-0.55 | — | — |
| Nov 13, 2025 | $-0.59 | $-0.83 | — | — |
| Aug 14, 2025 | $-1.00 | $-0.51 | — | — |
| May 13, 2025 | $-3.22 | $-0.58 | $2.6M | — |
| Mar 11, 2025 | $-1.68 | $-7.08 | — | $1.7M |
| Nov 14, 2024 | $-8.19 | $-8.64 | — | $2.0M |
News
HOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will present at Chardan's 10th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026, at 1:30 PM ET.
Tvardi Therapeutics (NASDAQ: TVRD - Get Free Report) and Phibro Animal Health (NASDAQ: PAHC - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings. Insider and Institutional Ownership 44.7% of
In a preclinical chronic colitis model, Tvardi's oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated STAT3-driven disease biology Collective findings now span multiple preclinical models of UC, further supporting the scientific rationale for advancing TTI-109, Tvardi's next-generation STAT3 inhibitor, in UC HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or …
HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events:
Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript
Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations
HOUSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that it will host a KOL webinar on Wednesday, August 19, 2026 at 11:00 AM ET featuring Randy Longman, MD, PhD (Weill Cornell Medicine), who will join Tvardi management to discuss the current tre…